Please enable JavaScript.
Coggle requires JavaScript to display documents.
PITUITARY TUMORS, PITUITARY GLAND - Coggle Diagram
PITUITARY TUMORS
pathophysiology
The main cause of pituitary tumours is still unknown although 2 theories were prevailed and the first one was that pituitary tumours shows or represents intrinsic abnormalities within the pituitary gland itself, and the second theory mostly favoured a hypothalamic cause for most if not all pituitary tumours, but most authorities favour the first hypothesis. studies have shown that pituitary tumours are monoclonal in origin ( alexander et al. 1990). normally tumours are caused by a single cell mutation which is followed by clonal expansion. pituitary adenomas is multi step process that includes proliferation of cell growth, differentiation and hormone secretion. if the pituitary tumour is an macroadenoma it may but pressure on vital organs and cause irregular hormone production in the body which in future may cause hormone deficiency and that when the body will require artificial hormone production.
-
-
NURSING CARE PLAN
-
-headache, nausea and vomiting , weakness, high blood pressure, high blood sugar,
-
relieve patient from headache within 24 hours, administer anti emetic to stop nausea and vomiting, low the levels of blood pressure and blood sugar within 4 hours.
-
assess the level of pain since the patient has been complaining of headache and administer analgesia to relive headache, encourage bedrest in order patient to gain energy, increase the intake of fluid, administer medication as prescribed by doctor in order to improve the patients condition.
-
patient was relieved from headache, blood pressure is back to normal ranges and blood sugar is also at normal ranges.
-
-
REFERENCES
google scholar, B M ARAFAH AND M P NASRALLAH
s R, Verhelst J, Master D, Van Acker K, Nobels F, Coolens JL,Mahler C & Beckers A 1998 Cabergoline in the treatment ofacromegaly: a study in 64 patients. Journal of ClinicalEndocrinology and Metabolism 83 374–378
Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366:914-924.
-
-